Literature DB >> 8509048

Non-specific immunological abnormalities and association of autoimmune diseases in idiopathic portal hypertension. A study by questionnaire.

K Saito1, Y Nakanuma, K Takegoshi, G Ohta, Y Obata, K Okuda, H Kameda.   

Abstract

A large survey by questionnaire of idiopathic portal hypertension (IPH) in Japan disclosed that 11.9% of 160 cases were associated with one or two autoimmune diseases, and 26.3% of them disclosed hypergammaglobulinemia. Patients with IPH also frequently showed one or more autoantibodies in the serum, such as antinuclear or anti-smooth muscle antibodies. These findings overlapped frequently in the same patient. These data imply that immunological disturbance and/or chronic antigenic stimulation are related to the pathogenesis of IPH, though the exact immunological mechanisms remain unclear. It will be necessary to study more specific immunological reactions in IPH.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8509048

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  22 in total

1.  Induction of elastin expression in vascular endothelial cells relates to hepatoportal sclerosis in idiopathic portal hypertension: possible link to serum anti-endothelial cell antibodies.

Authors:  Y Sato; X S Ren; K Harada; M Sasaki; H Morikawa; S Shiomi; M Honda; S Kaneko; Y Nakanuma
Journal:  Clin Exp Immunol       Date:  2012-03       Impact factor: 4.330

Review 2.  Clinical characteristics of idiopathic portal hypertension.

Authors:  Ozgur Harmanci; Yusuf Bayraktar
Journal:  World J Gastroenterol       Date:  2007-04-07       Impact factor: 5.742

Review 3.  Noncirrhotic portal hypertension.

Authors:  Harshal Rajekar; Rakesh K Vasishta; Yogesh K Chawla; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2011-11-09

Review 4.  Idiopathic Non-Cirrhotic Intrahepatic Portal Hypertension (NCIPH)-Newer Insights into Pathogenesis and Emerging Newer Treatment Options.

Authors:  Ashish Goel; Joshua E Elias; Chundamannil E Eapen; Banumathi Ramakrishna; Elwyn Elias
Journal:  J Clin Exp Hepatol       Date:  2014-07-28

Review 5.  The current clinical aspects of idiopathic portal hypertension.

Authors:  Tomohiro Tanaka; Yasuhiko Sugawara; Norihiro Kokudo
Journal:  Intractable Rare Dis Res       Date:  2013-08

Review 6.  Pathology of idiopathic non-cirrhotic portal hypertension.

Authors:  Maria Guido; Samantha Sarcognato; Diana Sacchi; Guido Colloredo
Journal:  Virchows Arch       Date:  2018-04-12       Impact factor: 4.064

7.  Noncirrhotic portal fibrosis/idiopathic portal hypertension: APASL recommendations for diagnosis and treatment.

Authors:  Shiv Kumar Sarin; Ashish Kumar; Yogesh Kumar Chawla; Sanjay Saran Baijal; Radha Krishna Dhiman; Wasim Jafri; Laurentius A Lesmana; Debendranath Guha Mazumder; Masao Omata; Huma Qureshi; Rizvi Moattar Raza; Peush Sahni; Puja Sakhuja; Mohammad Salih; Amal Santra; Barjesh Chander Sharma; Praveen Sharma; Gamal Shiha; Jose Sollano
Journal:  Hepatol Int       Date:  2007-09-11       Impact factor: 6.047

8.  Clinical features, serum interleukin-6, and interferon-gamma levels of 34 turkish patients with hepatoportal sclerosis.

Authors:  Aydin Seref Köksal; Seyfettin Köklü; Mehmet Ibiş; Mustafa Balci; Bahattin Ciçek; Nurgül Saşmaz; Burhan Sahin
Journal:  Dig Dis Sci       Date:  2007-04-03       Impact factor: 3.199

9.  Endothelial to mesenchymal transition via transforming growth factor-beta1/Smad activation is associated with portal venous stenosis in idiopathic portal hypertension.

Authors:  Azusa Kitao; Yasunori Sato; Seiko Sawada-Kitamura; Kenichi Harada; Motoko Sasaki; Hiroyasu Morikawa; Susumu Shiomi; Masao Honda; Osamu Matsui; Yasuni Nakanuma
Journal:  Am J Pathol       Date:  2009-07-16       Impact factor: 4.307

10.  Analysis of inherited thrombophilic mutations and natural anticoagulant deficiency in patients with idiopathic portal hypertension.

Authors:  Kadim Bayan; Yekta Tüzün; Serif Yilmaz; Naime Canoruc; Mehmet Dursun
Journal:  J Thromb Thrombolysis       Date:  2008-08-07       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.